{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-070901","form_type":"8-K","ticker":"CLYM","cik":"0001768446","company_name":"Climb Bio, Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.637958+00:00","generated_at":"2026-05-21T09:21:28.205553+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Climb Bio Q1 cash $197.8M; pipeline on track for 2025 milestones","bullets":["Cash and marketable securities $197.8M; expected to fund operations through 2027.","R&D expense $17.3M including $9.0M upfront to Mabworks for CLYM116 license.","Budoprutug Phase 2 pMN FDA-cleared; ITP and SLE trials on track for H1 2025 initiation.","CLYM116 IND/CTA submission expected H2 2025 with preclinical data in H2.","Appointed Kim Drapkin and Bo Cumbo as independent directors; Perrin Wilson as CBO."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-070901","json":"https://secwatch.observer/filing/0000950170-25-070901.json","markdown":"https://secwatch.observer/filing/0000950170-25-070901.md","text":"https://secwatch.observer/filing/0000950170-25-070901.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768446/000095017025070901/0000950170-25-070901-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768446/000095017025070901/clym-20250514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T09:21:28.205553+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}